August 15, 2012 — Sound Interventions Inc. has released three-month data from the company's first-in-human clinical study (SOUND-ITV) to treat resistant hypertension through the use of catheter-based ultrasound.
August 15, 2012 — Previously unreleased three-year data from the Zilver PTX randomized controlled trial of paclitaxel-eluting stents for femoropopliteal disease indicate that Cook Medical’s paclitaxel-eluting peripheral vascular stent demonstrated 83 percent freedom from TLR at 36 months in the PTX group, compared to 70.2 percent for patients treated with optimal percutaneous transluminal angioplasty and bare metal stents in the 479-patient study.
Due to the increasing number of transcatheter aortic valve replacements (TAVR) and endovascular aneurysm repair (EVAR), a new startup company has developed a transfemoral combined access and closure system to accomodate these larger sized percutaneous devices and arteriotomies.Â
If you enjoy this content, please share it with a colleague
August 14, 2012 — Berlin Heart announced that a study recently published in the New England Journal of Medicine (NEJM) concluded that survival using the Excor pediatric ventricular assist device (VAD) is "significantly greater" than the standard-of-care (extracorporeal membrane oxygenation, or ECMO) as a bridging therapy for children in need of a heart transplant.
August 14, 2012 — A study led by Kavitha Chinnaiyan, M.D., director of advanced cardiac imaging education, Beaumont Health System (Mich.), has shown that inappropriate CCTA (coronary computed tomography [CT] angiography) use can be reduced by 60 percent with educational programs, increased physician collaboration and close monitoring.
August 14, 2012 — The next five years will see many hospitals in Europe overcoming the high cost and complexity of implementing hybrid operating rooms (OR) by adopting better planning and budget allocation. This will encourage hospitals with larger cardiac and neurosurgery services to implement at least one hybrid OR, suggests new analysis from Frost & Sullivan.
August 14, 2012 — The U.S. Food and Drug Administration (FDA) has granted 510(k) market clearance to Stryker Neurovascular’s Trevo Pro Retriever, indicated for the removal of blood clots. It uses Stentriever technology to optimized clot integration and retrieval in patients experiencing acute ischemic stroke.
August 14, 2012 — Positron Corp. announced the transfer, consolidation and integration of its radiopharmaceutical operations from the Crown Point, Ind. facility to its Lubbock, Texas site.